Trabectome alternative for glaucoma surgery

Article

Trabectome, a device that ablates the arc of trabecular meshwork, is a safe and effective alternative to glaucoma surgery, according to a recent paper.

Trabectome, a device that ablates the arc of trabecular meshwork, is a safe and effective alternative to glaucoma surgery, according to a recent paper.

The investigation, led by Dr M. Maeda, Department of Ophthalmology, Gifu Red Cross Hospital, Gifu Social Insurance Chukyo Hospital, Nagoya, Japan, involved performing Trabectome surgeries on 80 eyes of 69 adult Japanese patients with or without previous surgery or laser treatment.

The team measured Goldmann applanation intraocular pressure (IOP), adjunctive medications, corneal endothelial cell density and best corrected visual acuity (BCVA). Intraoperative and postoperative adverse events were also recorded.

Mean preoperative IOP was 26.6±8.1 mmHg and decreased to a mean IOP of 17.4±3.4 mmHg six months after surgery. There were no complications such as choroidal effusion, choroidal haemorrhage or infection occurred.

Of the patients studied, 16.3% required surgical intervention and one case underwent cataract extraction during the follow-up period. There was an overall decrease of approximately 30% in IOP six months postoperatively.

The abstract can be viewed in the latest issue of the Journal of Glaucoma.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.